Literature DB >> 15298857

Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism.

Keira L Watts1, Monica A Spiteri.   

Abstract

Connective tissue growth factor (CTGF), a potent profibrotic mediator, acts downstream and in concert with transforming growth factor (TGF)-beta to drive fibrogenesis. Significant upregulation of CTGF has been reported in fibrogenic diseases, including idiopathic pulmonary fibrosis (IPF), and is partly responsible for associated excessive fibroblast proliferation and extracellular matrix deposition, but no effective therapy exists for averting such fibrogeneic events. Simvastatin has reported putative antifibrotic actions in renal fibroblasts; this study explores such actions on human IPF-derived and normal lung fibroblasts and examines associated driving mechanisms. Simvastatin reduces basal CTGF gene and protein expression in all fibroblast lines, overriding TGF-beta induction through inhibition of the cholesterol synthesis pathway. Signaling pathways driving simvastatin's effects on CTGF/TGF-beta interaction were evaluated using transient reporter transfection of a CTGF promoter construct. Inhibition of CTGF promoter activity by simvastatin was most marked at 10 muM concentration, reducing activity by 76.2 and 51.8% over TGF-beta-stimulated cultures in IPF and normal fibroblasts, respectively. We also show that geranylgeranylpyrophosphate (GGPP), but not farnesylpyrophosphate, induces CTGF promoter activity following simvastatin inhibition by 55.3 and 31.1% over GGPP-negative cultures in IMR90 and IPF-derived fibroblasts, respectively, implicating small GTPase Rho involvement rather than Ras in these effects. Indeed, the specific Rho inhibitor C3 exotoxin significantly (P < 0.05) suppressed TGF-beta-induced CTGF promoter activity in transfected lung fibroblasts, a finding further supported by transfection of dominant-negative and constitutively active RhoA constructs, thus demonstrating that simvastatin through a Rho signaling mechanism in lung fibroblasts can modulate CTGF expression and interaction with TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298857     DOI: 10.1152/ajplung.00447.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  31 in total

1.  Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis.

Authors:  William R Coward; Keira Watts; Carol A Feghali-Bostwick; Gisli Jenkins; Linhua Pang
Journal:  Mol Cell Biol       Date:  2010-04-19       Impact factor: 4.272

2.  Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein C-independent mechanism.

Authors:  Junru Wang; Marjan Boerma; Qiang Fu; Ashwini Kulkarni; Louis M Fink; Martin Hauer-Jensen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

3.  Biomechanical Regulation of Endothelium-dependent Events Critical for Adaptive Remodeling.

Authors:  Peter J Mack; Yuzhi Zhang; Seok Chung; Vernella Vickerman; Roger D Kamm; Guillermo García-Cardeña
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

4.  Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis.

Authors:  Katri Koli; Marjukka Myllärniemi; Kirsi Vuorinen; Kaisa Salmenkivi; Merja J Ryynänen; Vuokko L Kinnula; Jorma Keski-Oja
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

5.  Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey.

Authors:  Susan A Hall; Gretchen R Chiu; Carol L Link; William D Steers; Varant Kupelian; John B McKinlay
Journal:  Ann Epidemiol       Date:  2011-03       Impact factor: 3.797

6.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

Review 7.  Rho kinase inhibition in diabetic kidney disease.

Authors:  Radko Komers
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

Review 8.  Innovations in asthma therapy: is there a role for inhaled statins?

Authors:  Amir A Zeki; Mona Elbadawi-Sidhu
Journal:  Expert Rev Respir Med       Date:  2018-05-03       Impact factor: 3.772

Review 9.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

10.  Transforming growth factor-beta gene expression studies in nasal mucosal biopsies in naturally occurring allergic rhinitis.

Authors:  Rami J Salib
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.